Mutations within the tyrosine kinase domain of the EGFR gene, mainly deletions in exon 19 or substitution L858R in exon 21, are detected in ~10% of Caucasian patients with non-small cell lung cancer (NSCLC) (3). This evidence concerns the gene EGFR and non-small cell lung carcinoma.